For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$515.02
Thesis
Vertex runs a near-monopoly in cystic fibrosis with the Trikafta/Kaftrio franchise generating roughly $10B+ in annual revenue, funding one of biotech's most disciplined R&D engines. That cash flow is now backing a diversification beyond CF into gene editing and non-opioid pain, which transforms the story from a single-disease specialist into a multi-franchise platform.
Casgevy, partnered with CRISPR Therapeutics, is the first FDA-approved CRISPR/Cas9 therapy and addresses sickle cell disease and transfusion-dependent beta thalassemia. Journavx (suzetrigine), approved January 2025, is a first-in-class NaV1.8 inhibitor for moderate-to-severe acute pain, opening a non-opioid category the company can own commercially.
Catalysts
- Casgevy patient activations and authorized treatment center ramp
- Journavx adoption in post-surgical settings and label expansion into chronic pain
- Next-gen CF triple combo (vanzacaftor) cannibalization economics
- Pipeline readouts in APOL1-mediated kidney disease and type 1 diabetes cell therapy
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 19Trial initiationClinicalTrials.gov
Phase 3b trial NCT07890909 of Povetacicept autoinjector vs Sibeprenlimab syringe begins recruiting.
- Nov 18Trial initiationClinicalTrials.gov
Vertex initiates Phase 2/3 trial of povetacicept in primary membranous nephropathy (NCT07204275, recruiting).
- Nov 17Trial readoutClinicalTrials.gov
Vertex completes Phase 4 single-arm trial NCT06887959 of Suzetrigine for acute post-surgical pain.
- Nov 17Trial readoutClinicalTrials.gov
Vertex updates NCT06696443 Phase 3 long-term safety/efficacy trial of suzetrigine in painful DPN; status ACTIVE_NOT_RECRUITING as of 2026-11-17.
- Nov 16Trial readoutClinicalTrials.gov
Completed Phase 4 single-arm study NCT06887972 of suzetrigine for acute post-surgical pain
- Nov 2Financial resultsSEC
Vertex Pharmaceuticals 8-K (items 2.02, 9.01) reports results of operations.
- Oct 30OtherClinicalTrials.gov
Phase 3 trial NCT06696443 for long-term safety/effectiveness of suzetrigine in painful diabetic peripheral neuropathy updated to active, not recruiting.
- Oct 30Trial initiationClinicalTrials.gov
Vertex initiates phase 2/3 trial (NCT07204275) of povetacicept in primary membranous nephropathy; recruiting status as of 2026-10-30.